Psychotropic Medications

Christopher T. Manetta; Julie P. Gentile

doi:10.1002/9781119945925.ch12

Psychotropic Medications

Christopher T. Manetta, Julie P. Gentile

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Many individual with intellectual disability (ID) can collaborate and communicate opinionsregarding pharmacologic interventions. Like those with typical cognitive ability, they sufferphysical and emotional pain, complicated by varying limitations in communication, and intheir ability to meet basic needs and in navigating social settings. Their communicativeabilities are affected by their degree of ID, ranging from mild to profound, but all individualsshould be afforded the opportunity to communicate their thoughts about treatment in theirown ways and within their developmental frameworks.

Original language	English
Title of host publication	Psychiatry of Intellectual Disability
Subtitle of host publication	A Practical Manual
Publisher	John Wiley and Sons
Pages	250-277
Number of pages	28
ISBN (Print)	9781119993810
DOIs	https://doi.org/10.1002/9781119945925.ch12
State	Published - Mar 27 2012

ASJC Scopus Subject Areas

General Medicine

Keywords

Behavioral treatment modalities in "habit disorders"
Biopsychosocial formulation, improving quality of life
Biopsychosocial, family/caretakers/guardians
Comorbid psychiatric disorders, and habit disorders
Non-pharmacological interventions
Patients with ID, vulnerable to antipsychotics
Psychiatric and behavioral problems, much more with ID
Psychotropic medications
Psychotropic medications, for cognitive functioning

Disciplines

Mental Disorders
Other Psychiatry and Psychology
Psychiatry

Access to Document

10.1002/9781119945925.ch12

https://doi.org/10.1002/9781119945925.ch12

Cite this

@inbook{1b3b41c9f75140c69afddc46cc9eeb62,

title = "Psychotropic Medications",

abstract = " Many individual with intellectual disability (ID) can collaborate and communicate opinionsregarding pharmacologic interventions. Like those with typical cognitive ability, they sufferphysical and emotional pain, complicated by varying limitations in communication, and intheir ability to meet basic needs and in navigating social settings. Their communicativeabilities are affected by their degree of ID, ranging from mild to profound, but all individualsshould be afforded the opportunity to communicate their thoughts about treatment in theirown ways and within their developmental frameworks.",

keywords = "Behavioral treatment modalities in {"}habit disorders{"}, Biopsychosocial formulation, improving quality of life, Biopsychosocial, family/caretakers/guardians, Comorbid psychiatric disorders, and habit disorders, Non-pharmacological interventions, Patients with ID, vulnerable to antipsychotics, Psychiatric and behavioral problems, much more with ID, Psychotropic medications, Psychotropic medications, for cognitive functioning",

author = "Manetta, {Christopher T.} and Gentile, {Julie P.}",

year = "2012",

month = mar,

day = "27",

doi = "10.1002/9781119945925.ch12",

language = "English",

isbn = "9781119993810",

pages = "250--277",

booktitle = "Psychiatry of Intellectual Disability",

publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Psychotropic Medications

AU - Manetta, Christopher T.

AU - Gentile, Julie P.

PY - 2012/3/27

Y1 - 2012/3/27

N2 - Many individual with intellectual disability (ID) can collaborate and communicate opinionsregarding pharmacologic interventions. Like those with typical cognitive ability, they sufferphysical and emotional pain, complicated by varying limitations in communication, and intheir ability to meet basic needs and in navigating social settings. Their communicativeabilities are affected by their degree of ID, ranging from mild to profound, but all individualsshould be afforded the opportunity to communicate their thoughts about treatment in theirown ways and within their developmental frameworks.

AB - Many individual with intellectual disability (ID) can collaborate and communicate opinionsregarding pharmacologic interventions. Like those with typical cognitive ability, they sufferphysical and emotional pain, complicated by varying limitations in communication, and intheir ability to meet basic needs and in navigating social settings. Their communicativeabilities are affected by their degree of ID, ranging from mild to profound, but all individualsshould be afforded the opportunity to communicate their thoughts about treatment in theirown ways and within their developmental frameworks.

KW - Behavioral treatment modalities in "habit disorders"

KW - Biopsychosocial formulation, improving quality of life

KW - Biopsychosocial, family/caretakers/guardians

KW - Comorbid psychiatric disorders, and habit disorders

KW - Non-pharmacological interventions

KW - Patients with ID, vulnerable to antipsychotics

KW - Psychiatric and behavioral problems, much more with ID

KW - Psychotropic medications

KW - Psychotropic medications, for cognitive functioning

UR - http://www.scopus.com/inward/record.url?scp=84886105283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886105283&partnerID=8YFLogxK

UR - https://corescholar.libraries.wright.edu/psychiatry/34

UR - https://doi.org/10.1002/9781119945925.ch12

U2 - 10.1002/9781119945925.ch12

DO - 10.1002/9781119945925.ch12

M3 - Chapter

AN - SCOPUS:84886105283

SN - 9781119993810

SP - 250

EP - 277

BT - Psychiatry of Intellectual Disability

PB - John Wiley and Sons

ER -

Psychotropic Medications

Abstract

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

Other files and links

Cite this